Celldex Therapeutics Inc. logo

CLDX

Celldex Therapeutics Inc.

$33.87

Earnings Summary

Revenue
$0.17Mn
Net Profits
$-23.05Mn
Net Profit Margins
-13247.13%

Highlights

Revenue:

Celldex Therapeutics Inc.’s revenue fell -74.6% since last year same period to $0.17Mn in the Q1 2022. On a quarterly growth basis, Celldex Therapeutics Inc. has generated -47.9% fall in its revenue since last 3-months.

Net Profits:

Celldex Therapeutics Inc.’s net profit fell -39.38% since last year same period to $-23.05Mn in the Q1 2022. On a quarterly growth basis, Celldex Therapeutics Inc. has generated -14.4% fall in its net profits since last 3-months.

Net Profit Margins:

Celldex Therapeutics Inc.’s net profit margin fell -448.69% since last year same period to -13247.13% in the Q1 2022. On a quarterly growth basis, Celldex Therapeutics Inc. has generated -119.6% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Celldex Therapeutics Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.51
EPS Estimate Current Year
-0.51

Highlights

EPS Estimate Current Quarter:

Celldex Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.51 - a -13.33% fall from last quarter’s estimates.

EPS Estimate Current Year:

Celldex Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -0.51.

Key Ratios

Key ratios of the Celldex Therapeutics Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
-0.49
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
-0.36
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Celldex Therapeutics Inc.’s earning per share (EPS) fell -16.67% since last year same period to -0.49 in the Q1 2022. This indicates that the Celldex Therapeutics Inc. has generated -16.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Celldex Therapeutics Inc.’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Celldex Therapeutics Inc.’s return on equity (ROE) stands at -0.36.

Dividend Per Share (DPS):

Celldex Therapeutics Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.45
-0.49
-8.89%

Company Information

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Organisation
Celldex Therapeutics Inc.
Headquarters
Hampton, New Jersey, US
Employees
124
Industry
Health Technology
CEO
Anthony Marucci